Potential Gains in Life Expectancy (LE) Associated with Achieving Treatment Goals in People with Type 2 Diabetes (T2D) in the U.S.
In this medfyle
Expert commentary by Elizabeth T. Jensen, MPH, PhD
This Medfyle was published more than two years ago. More recent Medfyle on this topic may now be available.
Acknowledgements
This is a highlights summary of an oral session given at the ADA 2021 - 81st Scientific Sessions and presented by:
Hui Shao, MD, PhD
University of Florida
Gainesville, FL, USA
The content is produced by Infomedica, the official reporting partner of ADA 2021.
The presenting authors of the original session had no part in the creation of this conference highlights summary.
In addition, an expert commentary on the topic has been provided by:
Elizabeth T. Jensen, MPH, PhD
Associate Professor of Epidemiology
Department of Epidemiology and Prevention
Wake Forest School of Medicine, Winston-Salem, NC, USA
About the Expert
Elizabeth T. Jensen, MPH, PhD
Associate Professor of Epidemiology
Department of Epidemiology and Prevention
Wake Forest School of Medicine, Winston-Salem, NC, USA
Dr. Jensen is a reproductive, perinatal, pediatric epidemiologist with additional training in biomarker-based epidemiology. Her research primarily focuses on etiologic factors in the development of pediatric, immune-mediated chronic disease, including understanding factors contributing to disparities in health outcomes. Dr. Jensen earned both her MPH and PhD from the University of North Carolina at Chapel Hill and completed a postdoctoral fellowship with the National Institute of Environmental Health Sciences (NIEHS). In addition to her appointment in Epidemiology and Prevention at Wake Forest School of Medicine, she holds a joint appointment in the Department of Internal Medicine and an adjunct appointment at the University of North Carolina at Chapel Hill in the Department of Medicine. Dr. Jensen co-leads the coordinating center for the SEARCH for Diabetes in Youth cohort study, and is PI for a SEARCH ancillary study of perfluorinated alkyl substances, metabolomics, and cardiovascular disease risk in diabetes, supported through the Children’s Health Exposure Assessment Resource (CHEAR).
Disclosures: nothing to disclose
References
1.Seshsai SRK, Kaptoge S, Thomson A, et al. Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med 2011;364(9):829–41.
2. Leal J, Gray AM, Clarke PM. Development of life-expectancy tables for people with type 2 diabetes. Eur Heart J 2009;30(7):834–9.
3. Shao H, Fonseca V, Stoecker C, et al. Novel Risk Engine for Diabetes Progression and Mortality in USA: Building, Relating, Assessing, and Validating Outcomes (BRAVO). Pharmacoeconomics 2018;36(9):1125–34.
4. Shao H, Yang S, Fonseca V, et al. Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation. Pharmacoeconomics 2019;37:921–9.
5. Shao H, Lin J, Zhou X, et al. Influence of Diabetes Complications on HbA1c Treatment Goals Among Older U.S. Adults: A Cost-effectiveness Analysis. Diabetes Care 2019;42(11):2136–42.
